RD125 / IASO BIO - LARVOL DELTA

Efficacy and safety of autologous CD5-KO anti-CD5 CAR-T cells in relapsed/refractory CD5+ hematological malignancies. (PubMed, Cell Rep Med) - P1 | "These findings demonstrate CT125A's therapeutic potential in CD5+ malignancies while highlighting the need for safety optimization. The trial has been registered at ClinicalTrials.gov (NCT04767308)."

Journal • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Oncology • CD4 • CD5 • CD8

First-in-human Phase I study of autologous CD5-knockout anti-CD5 CAR-T cells in CD5⁺ hematologic malignancies (ASH 2025) - P1 | "Two primary clinical studies have reported on CD5-targeted CAR-T therapy: one usingautologous CAR-T cells without CD5 editing (NCT03081910) and one using allogeneic CD5-knockout (CD5-KO) CAR-T cells (NCT05032599). However, sustained CD5+ T cells depletion and expansion of CD5- T cells mayimpair immune regulation and infection control in patients. These findings highlight the need tomodulate the CAR-T persistence duration clinical application and support the consideration ofconsolidative HSCT therapy in patients achieving remission."

CAR T-Cell Therapy • First-in-human • P1 data • Bone Marrow Transplantation • Dental Disorders • Diffuse Large B Cell Lymphoma • Endocrine Disorders • Hematological Malignancies • Immunology • Infectious Disease • Nephrology • Neutropenia • Oncology • Renal Disease • Thrombocytopenia • Xerostomia • CD4 • CD8

IASO Biotherapeutics Publishes Preclinical Results of Its CD5-Targeting CAR-T in American Society of Gene & Cell Therapy’s Journal, Molecular Therapy (Businesswire) - “IASO Biotherapeutics…announced that the preclinical results of the company’s proprietary next-generation chimeric antigen receptor (CAR)-T cell therapy, CT125A, were recently published in Molecular Therapy, an internationally renowned peer-reviewed scientific journal…Researchers of the study successfully selected CD5-targeting fully human heavy-chain variable (FHVH) domains from a phage display library, and knocked out CD5 from those T cells using CRISPR/Cas9 technology, overcoming self-activation and fratricide problems on CAR-T cells. A series of in vivo and in vitro functional comparisons validated the hypothesis that tandem VH domains targeting different epitopes could potentially enhance the function of CAR-T cells, and CT125A, with its biepitopic FHVH3/VH1 CAR-T cells, offers a promising new strategy for the treatment of T cell malignancies.”

Preclinical • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies (clinicaltrials.gov) - P1; N=18; Not yet recruiting; Sponsor: Huazhong University of Science and Technology

Clinical • New P1 trial • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma